Skip to content

Acute Posterior Circulation Stroke with Large Infarct Core: A Multi-center, Prospective, Chinese Cohort of Mechanical Thrombectomy in Acute Posterior Circulation Stroke

Acute Posterior Circulation Stroke with Large Infarct Core: A Multi-center, Prospective, Chinese Cohort of Mechanical Thrombectomy in Acute Posterior Circulation Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089266
Enrollment
Unknown
Registered
2024-09-04
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Sponsors

The Second Affiliated Hospital of the Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Ages = 18 years; 2. Present less than 24 hours of stroke onset or last seen well; 3. Clinical diagnosis of AIS due to posterior circulation large vessel occlusion on DSA/CTA/MRA; 4. Alberta Stroke Program Early CT Score (ASPECTS)=5 on CT/MRI; 5. National Institute of Health stroke scale (NIHSS) =6; 6. Informed consent obtained from patients or their legal representatives.

Exclusion criteria

Exclusion criteria: 1. Confirmed intracranial hemorrhage through computed tomography (CT) or magnetic resonance imaging (MRI); 2. Received Intravenous Thrombolysis; 3. Pre-stroke modified Rankin Scale (mRS) score = 2; 4. Pregnancy or breastfeeding women; 5. Allergy to contrast agents; 6. Currently participating in other clinical trials; 7. Systolic blood pressure > 185mmHg or diastolic blood pressure > 110mmHg, and oral antihypertensive drugs cannot control it; 8. Genetic or acquired bleeding diathesis, deficiency of anticoagulant factors, or use of anticoagulant medication with an International Normalized Ratio (INR) > 3; 9. Blood glucose 22.2mmol/L (400mg/dl),platelets <100*10^9/L or Hct<25%; 10. History of bleeding within the past month; 11. Any end-stage disease with expected survival less than 6 months; 12. Anticipated inability to complete follow-up; 13. Intracranial aneurysm, arteriovenous malformation; 14. Presence of intracranial tumors with mass effect on imaging (excluding small meningiomas); 15. Brain herniation causing midline shift; 16. Presence of severe complications that may affect patient prognosis and follow-up (cancer, severe heart failure, renal failure). <br

Design outcomes

Primary

MeasureTime frame
Shift in the distribution of mRS scores at 90 days;

Secondary

MeasureTime frame
The rate of 90-day modified Rankin scale (mRS) score 0-3(%);The rate of 90-day modified Rankin scale (mRS) score 0-2(%);The rate of 90-day modified Rankin scale (mRS) score 0-1(%);EQ-5D scale score;Symptomatic intracranial hemorrhage;any intracranial hemorrhage;The rate of death;

Countries

China

Contacts

Public ContactZi Wenjie

The Second Affiliated Hospital of the Army Medical University

ziwenjie1981@163.com+86 185 2303 3816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026